Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
RBA Unlikely to Cut Interest Rates in 2026 as Inflation Pressures Persist, Says Westpac 
Chinese Robotaxi Stocks Rally as Tesla Boosts Autonomous Driving Optimism 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
U.S. Stock Futures Edge Higher as Micron Earnings Boost AI Sentiment Ahead of CPI Data 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores 
Asian Currencies Trade Sideways as Dollar Weakens Ahead of Key U.S. Data 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
Japan Inflation Holds Firm in November as BOJ Nears Key Rate Hike Decision 
Samsung Biologics, South Korea's biotech behemoth, expands its portfolio in a $1.08 billion deal with U.S. pharma titan, Pfizer, marking a landmark in global biotech manufacturing. The enhanced partnership will leverage Samsung's newest facility to produce Pfizer's multiproduct biosimilar portfolio.
This includes a new contract signed with Pfizer, building upon the initial deal established in March. Under the new agreement, Samsung Biologics will manufacture an additional $193 million of Pfizer products.
Additionally, Samsung Biologics will produce Pfizer's multiproduct biosimilar portfolio, encompassing oncology, inflammation, and immunotherapy, with a value of $704 million. The company will extend its manufacturing capabilities to provide Pfizer ample capacity for large-scale production of a multiproduct biosimilar portfolio.
This strategic collaboration will occur at Samsung Biologics' newest facility, Plant 4, in Songdo, South Korea. Completing the 240,000-liter biomanufacturing plant in June 2023 marks a significant milestone in the continued growth of Samsung Biologics.
Mike McDermott, Chief Global Supply Officer and Executive Vice President at Pfizer, expressed his enthusiasm for the partnership, stating they are pleased to extend the strategic collaboration with Pfizer as we share and support their strong vision to bring innovative solutions for patients around the globe.
These manufacturing partnerships solidify Samsung Biologics' position in the global contract development and manufacturing organization (CDMO) market. As part of its expansion strategy, the company is increasing its production capacity and aims to become a major player in the industry.
The contracts with Pfizer highlight the long-term strategic partnership between the two companies, further establishing Samsung Biologics as a trusted collaborator. The company plans to explore new avenues in overseas markets by considering opening new sales offices to facilitate communication with global customers. With an existing office in New Jersey and a research and development center in San Francisco, Samsung Biologics is set for continued growth on a global scale.
